z-logo
Premium
Immunohistochemistry using the BRAF V600E mutation‐specific monoclonal antibody VE 1 is not a useful surrogate for genotyping in colorectal adenocarcinoma
Author(s) -
Adackapara Cheryl A,
Sholl Lynette M,
Barletta Justine A,
Hornick Jason L
Publication year - 2013
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1111/his.12154
Subject(s) - immunohistochemistry , monoclonal antibody , genotyping , adenocarcinoma , mutation , epitope , monoclonal , cancer research , antibody , microbiology and biotechnology , medicine , pathology , biology , immunology , genotype , cancer , genetics , gene
Aims The presence of a BRAF mutation is a strong marker for poor prognosis of colorectal carcinoma ( CRC ), and can be used as evidence of a sporadic mechanism of mismatch repair deficiency. BRAF mutation may also predict resistance to EGFR ‐targeted therapy. A BRAF V600E‐specific antibody has recently become commercially available. The aim of this study was to determine whether immunohistochemistry can predict BRAF mutations in CRC . Methods and results Immunohistochemistry was performed on 52 genotyped CRC cases (17 BRAF mutant, 18 KRAS mutant, 17 BRAF / KRAS wild‐type) with monoclonal antibody VE 1. Cytoplasmic staining was observed in 71% of BRAF V600E mutant tumours (moderate or strong staining in 50% of these cases). Weak cytoplasmic staining was observed in 17% of KRAS mutant tumours and 35% of wild‐type tumours. Non‐specific nuclear staining was common. The sensitivity and specificity of immunohistochemistry with VE 1 for BRAF mutation were 71% and 74%, respectively; when only moderate or strong staining was considered to be positive, the specificity was 100%, but the sensitivity only 35%. Conclusions Immunohistochemistry with VE 1 is not a useful surrogate for genotyping in CRC . Although moderate or strong cytoplasmic staining is specific for BRAF V600E mutations, this antibody is insufficiently sensitive to serve as an effective screening tool.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here